TherapeuticsMD, Inc. (TXMD)
USD 1.03
(4.06%)
USD 1.03
(4.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.3 Million USD | -99.45% |
| 2022 | 68.56 Million USD | 0.67% |
| 2021 | 68.11 Million USD | 39.3% |
| 2020 | 48.89 Million USD | 12.89% |
| 2019 | 43.31 Million USD | 224.15% |
| 2018 | 13.36 Million USD | -5.51% |
| 2017 | 14.14 Million USD | -6.79% |
| 2016 | 15.17 Million USD | -2.98% |
| 2015 | 15.63 Million USD | 37.71% |
| 2014 | 11.35 Million USD | 66.58% |
| 2013 | 6.81 Million USD | 175.96% |
| 2012 | 2.46 Million USD | 116.46% |
| 2011 | 1.14 Million USD | 4911.57% |
| 2010 | -23.71 Thousand USD | 27.22% |
| 2009 | -32.58 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 799.9 Thousand USD | 20.76% |
| 2005 | 662.39 Thousand USD | 54.14% |
| 2004 | 429.74 Thousand USD | 40.07% |
| 2003 | 306.79 Thousand USD | 46.41% |
| 2002 | 209.53 Thousand USD | -3.16% |
| 2001 | 216.38 Thousand USD | -22.75% |
| 2000 | 280.1 Thousand USD | 89.7% |
| 1999 | 147.65 Thousand USD | 18.14% |
| 1998 | 124.99 Thousand USD | -17.92% |
| 1997 | 152.27 Thousand USD | -37.61% |
| 1996 | 244.05 Thousand USD | 74.01% |
| 1995 | 140.25 Thousand USD | -3.14% |
| 1994 | 144.79 Thousand USD | 2.09% |
| 1993 | 141.83 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 180 Thousand USD | 233.33% |
| 2024 Q2 | 54 Thousand USD | 30.0% |
| 2023 Q2 | 309 Thousand USD | -20.57% |
| 2023 Q3 | -183 Thousand USD | -159.22% |
| 2023 Q4 | -135 Thousand USD | 26.23% |
| 2023 Q1 | 389 Thousand USD | 117.05% |
| 2023 FY | 380 Thousand USD | -99.45% |
| 2022 FY | 68.56 Million USD | 0.67% |
| 2022 Q4 | -2.28 Million USD | -113.32% |
| 2022 Q3 | 17.12 Million USD | -28.09% |
| 2022 Q1 | 14.47 Million USD | 3.82% |
| 2022 Q2 | 23.82 Million USD | 64.59% |
| 2021 Q3 | 20.12 Million USD | 6.65% |
| 2021 Q2 | 18.86 Million USD | 24.31% |
| 2021 Q1 | 15.17 Million USD | -10.7% |
| 2021 Q4 | 13.94 Million USD | -30.72% |
| 2021 FY | 68.11 Million USD | 39.3% |
| 2020 FY | 48.89 Million USD | 12.89% |
| 2020 Q1 | 9.53 Million USD | -26.78% |
| 2020 Q2 | 6.3 Million USD | -33.93% |
| 2020 Q3 | 16.06 Million USD | 154.97% |
| 2020 Q4 | 16.99 Million USD | 5.81% |
| 2019 Q1 | 3.18 Million USD | -23.07% |
| 2019 Q3 | 22.27 Million USD | 361.19% |
| 2019 FY | 43.31 Million USD | 224.15% |
| 2019 Q2 | 4.83 Million USD | 51.7% |
| 2019 Q4 | 13.02 Million USD | -41.54% |
| 2018 Q4 | 4.13 Million USD | 49.18% |
| 2018 Q2 | 3.3 Million USD | 5.39% |
| 2018 Q1 | 3.13 Million USD | -11.04% |
| 2018 Q3 | 2.77 Million USD | -16.15% |
| 2018 FY | 13.36 Million USD | -5.51% |
| 2017 Q2 | 3.56 Million USD | 7.3% |
| 2017 FY | 14.14 Million USD | -6.79% |
| 2017 Q4 | 3.52 Million USD | -5.04% |
| 2017 Q3 | 3.71 Million USD | 4.15% |
| 2017 Q1 | 3.32 Million USD | -11.96% |
| 2016 Q1 | 3.82 Million USD | -13.02% |
| 2016 Q2 | 3.27 Million USD | -14.35% |
| 2016 Q3 | 4.29 Million USD | 31.32% |
| 2016 Q4 | 3.77 Million USD | -12.11% |
| 2016 FY | 15.17 Million USD | -2.98% |
| 2015 Q2 | 3.81 Million USD | 11.17% |
| 2015 FY | 15.63 Million USD | 37.71% |
| 2015 Q4 | 4.39 Million USD | 9.95% |
| 2015 Q3 | 3.99 Million USD | 4.75% |
| 2015 Q1 | 3.43 Million USD | 1.58% |
| 2014 FY | 11.35 Million USD | 66.58% |
| 2014 Q2 | 2.85 Million USD | 42.95% |
| 2014 Q3 | 3.11 Million USD | 9.05% |
| 2014 Q1 | 1.99 Million USD | -16.52% |
| 2014 Q4 | 3.37 Million USD | 8.35% |
| 2013 FY | 6.81 Million USD | 175.96% |
| 2013 Q4 | 2.39 Million USD | 45.51% |
| 2013 Q3 | 1.64 Million USD | 1.8% |
| 2013 Q2 | 1.61 Million USD | 39.8% |
| 2013 Q1 | 1.15 Million USD | 27.41% |
| 2012 Q3 | 729.61 Thousand USD | 63.3% |
| 2012 Q4 | 907.93 Thousand USD | 24.44% |
| 2012 Q2 | 446.78 Thousand USD | 15.88% |
| 2012 Q1 | 385.56 Thousand USD | -66.15% |
| 2012 FY | 2.46 Million USD | 116.46% |
| 2011 Q3 | 2100.00 USD | 0.0% |
| 2011 FY | 1.14 Million USD | 4911.57% |
| 2011 Q1 | - USD | 100.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | 1.13 Million USD | 54136.43% |
| 2010 Q2 | -1209.00 USD | -107.89% |
| 2010 Q4 | -12 Thousand USD | -14.24% |
| 2010 Q3 | -10.5 Thousand USD | -768.9% |
| 2010 Q1 | 15.32 Thousand USD | 147.05% |
| 2010 FY | -23.71 Thousand USD | 27.22% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | -32.58 Thousand USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | -32.58 Thousand USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q3 | 168.49 Thousand USD | 3.43% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q2 | 162.9 Thousand USD | 11.28% |
| 2007 Q1 | 146.39 Thousand USD | -18.26% |
| 2006 Q1 | 167.04 Thousand USD | -23.54% |
| 2006 Q3 | 294.98 Thousand USD | 94.63% |
| 2006 FY | 799.9 Thousand USD | 20.76% |
| 2006 Q4 | 179.09 Thousand USD | -39.29% |
| 2006 Q2 | 151.56 Thousand USD | -9.27% |
| 2005 Q1 | 147.76 Thousand USD | -10.32% |
| 2005 Q2 | 88.07 Thousand USD | -40.4% |
| 2005 FY | 662.39 Thousand USD | 54.14% |
| 2005 Q3 | 208.09 Thousand USD | 136.28% |
| 2005 Q4 | 218.46 Thousand USD | 4.99% |
| 2004 Q4 | 164.77 Thousand USD | 49.8% |
| 2004 Q1 | 95.24 Thousand USD | 7.21% |
| 2004 Q2 | 68.19 Thousand USD | -28.4% |
| 2004 Q3 | 109.99 Thousand USD | 61.29% |
| 2004 FY | 429.74 Thousand USD | 40.07% |
| 2003 Q2 | 84.58 Thousand USD | 15.28% |
| 2003 FY | 306.79 Thousand USD | 46.41% |
| 2003 Q4 | 88.84 Thousand USD | 48.09% |
| 2003 Q3 | 59.99 Thousand USD | -29.07% |
| 2003 Q1 | 73.37 Thousand USD | 5.42% |
| 2002 Q4 | 69.59 Thousand USD | 29.69% |
| 2002 Q1 | 35.3 Thousand USD | 26.37% |
| 2002 Q2 | 50.96 Thousand USD | 44.35% |
| 2002 FY | 209.53 Thousand USD | -3.16% |
| 2002 Q3 | 53.66 Thousand USD | 5.3% |
| 2001 Q2 | 65.58 Thousand USD | -13.25% |
| 2001 Q1 | 75.6 Thousand USD | -32.34% |
| 2001 FY | 216.38 Thousand USD | -22.75% |
| 2001 Q4 | 27.94 Thousand USD | -40.86% |
| 2001 Q3 | 47.24 Thousand USD | -27.97% |
| 2000 Q3 | 68.11 Thousand USD | 31.51% |
| 2000 Q2 | 51.79 Thousand USD | -25.92% |
| 2000 Q1 | 69.91 Thousand USD | 80.07% |
| 2000 FY | 280.1 Thousand USD | 89.7% |
| 2000 Q4 | 111.74 Thousand USD | 64.06% |
| 1999 Q1 | 40.24 Thousand USD | 0.0% |
| 1999 Q3 | 42.25 Thousand USD | 9.87% |
| 1999 Q2 | 38.46 Thousand USD | -4.42% |
| 1999 FY | 147.65 Thousand USD | 18.14% |
| 1999 Q4 | 38.82 Thousand USD | -8.12% |
| 1998 FY | 124.99 Thousand USD | -17.92% |
| 1997 FY | 152.27 Thousand USD | -37.61% |
| 1996 FY | 244.05 Thousand USD | 74.01% |
| 1995 FY | 140.25 Thousand USD | -3.14% |
| 1994 FY | 144.79 Thousand USD | 2.09% |
| 1993 FY | 141.83 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 99.601% |
| Embecta Corp. | 749.9 Million USD | 99.826% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 99.574% |
| Dynavax Technologies Corporation | 182.11 Million USD | 99.285% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 98.218% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 99.734% |
| PainReform Ltd. | -15 Thousand USD | 8780.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 95.624% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 84.387% |
| SCYNEXIS, Inc. | 124.51 Million USD | 98.954% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -135.03% |
| Cosmos Health Inc. | 4.34 Million USD | 70.066% |
| Journey Medical Corporation | 52.52 Million USD | 97.521% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 84.387% |
| Safety Shot Inc | -74.45 Thousand USD | 1848.66% |
| Alpha Teknova, Inc. | 10.29 Million USD | 87.354% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.698% |
| Bright Green Corporation | -237.01 Thousand USD | 649.33% |
| Procaps Group, S.A. | 239.56 Million USD | 99.457% |
| Theratechnologies Inc. | 62.12 Million USD | 97.904% |
| Harrow Health, Inc. | 90.55 Million USD | 98.562% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 72.561% |
| Biofrontera Inc. | 16.62 Million USD | 92.169% |
| DURECT Corporation | 6.83 Million USD | 80.94% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.751% |
| Cronos Group Inc. | 6.99 Million USD | 81.376% |
| OptiNose, Inc. | 62.35 Million USD | 97.912% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.705% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 529.703% |
| RedHill Biopharma Ltd. | 3.05 Million USD | 57.37% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 99.58% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | 75.864% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 96.112% |
| Radius Health, Inc. | 307.71 Million USD | 99.577% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 87.081% |
| ProPhase Labs, Inc. | 16.23 Million USD | 91.982% |
| Phibro Animal Health Corporation | 312.48 Million USD | 99.583% |
| Procaps Group S.A. | 239.56 Million USD | 99.457% |
| Alvotech | -69.42 Million USD | 101.875% |
| Viatris Inc. | 6.43 Billion USD | 99.98% |
| Rockwell Medical, Inc. | 8.7 Million USD | 85.041% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 97.615% |
| SIGA Technologies, Inc. | 122.09 Million USD | 98.934% |
| Tilray Brands, Inc. | 223.35 Million USD | 99.417% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 96.889% |
| Shineco, Inc. | 882.16 Thousand USD | -47.591% |
| PetIQ, Inc. | 252.74 Million USD | 99.485% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 274.627% |
| Incannex Healthcare Limited | 12 Thousand USD | -10750.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.93% |
| Alimera Sciences, Inc. | 61.17 Million USD | 97.872% |
| Silver Spike Investment Corp. | 8.1 Million USD | 83.931% |
| Assertio Holdings, Inc. | 125.04 Million USD | 98.959% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 19216.136% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | 68.935% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | 80.14% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 154.021% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 95.199% |
| Hempacco Co., Inc. | -1.21 Million USD | 207.087% |
| Talphera, Inc. | -4.89 Million USD | 126.599% |
| Alvotech | -69.42 Million USD | 101.875% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 99.413% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.817% |
| Currenc Group, Inc. | 17.35 Million USD | 92.498% |
| Kamada Ltd. | 52.59 Million USD | 97.524% |
| Indivior PLC | 907 Million USD | 99.856% |
| Evoke Pharma, Inc. | 4.97 Million USD | 73.849% |
| Flora Growth Corp. | 17.73 Million USD | 92.66% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 154.021% |
| Evolus, Inc. | 140.52 Million USD | 99.073% |
| HUTCHMED (China) Limited | 453.55 Million USD | 99.713% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 99.621% |
| Akanda Corp. | 111.44 Thousand USD | -1068.247% |